SciClone Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

SCLN 7.79 +0.08 (1.04%)
price chart
Fair Value for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) will report their fourth quarter earnings results on March 11. With that in mind, we look to see how the stock is priced based on current analyst expectations from a fundamental growth and value perspective.
Update: SciClone Pharmaceuticals Exceeds Earnings Estimates For Q3 (SCLN)
What matters is that sales of the company's leading product, Zadaxin increased 28.4% to $32.1 million year-over-year. This shows that demand for the drug has increased at a strong pace.
Related articles »  
Buy, Sell, or Hold: SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) develops and commercializes novel medicines for treating a broad range of the world's most serious diseases.
SciClone Pharmaceuticals, Inc. Analyst Rating Update
Analysts at Zacks have given a Neutral rating on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) with a rating of 3. The counter has received an average rating of 3 from 1 brokerage firms.
SciClone Pharmaceuticals, Inc. Short Interest Drops by -0.4%  Markets Bureau
Must Watch These 5 Stocks: Zynga Inc (NASDAQ:ZNGA), CBS Corporation ...  Property Mentor
Company Shares of SciClone Pharmaceuticals, Inc. Rally 1.63%
Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) rose by 1.63% in the past week and 0.27% for the past 4 weeks.
Brokerage Firm Rating Disclosure Update on SciClone Pharmaceuticals, Inc.  Bar and Graph Report
Share Price of SciClone Pharmaceuticals, Inc. Rally 0.39%
Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) rose by 0.39% in the past week and 4.47% for the last 4 weeks.
Shares of SciClone Pharmaceuticals, Inc. Sinks by -0.41% for the Week
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has lost 0.41% during the past week and dropped 15.66% in the past 4 weeks.
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2014 Results ...
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2014 Results - Earnings Call Transcript. Nov. 10, 2014 9:47 PM ET | About: SciClone Pharmaceuticals, Inc. (SCLN) by: SA Transcripts. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).
Related articles »  
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter ...
FOSTER CITY, CA--(Marketwired - Feb 25, 2015) - SciClone Pharmaceuticals, Inc. ( NASDAQ : SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2014 on Wednesday, March 11, 2015.
SciClone Pharmaceuticals: Promising Biotech With China Exposure
SciClone Pharmaceuticals (NASDAQ:SCLN) is a $271.89 million small-cap biotech company based in the United States, but primarily focused on selling drugs in China.
Related articles »